A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging

Amin Hajitou; Dina C. Lev; Jonathan A.F. Hannay; Borys Korchin; Fernanda I. Staquicini; Suren Soghomonyan; Mian M. Alauddin; Robert S. Benjamin; Raphael E. Pollock; Juri G. Gelovani; Renata Pasqualini; Wadih Arap

doi:10.1073/pnas.0712184105

A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging

Amin Hajitou, Dina C. Lev, Jonathan A.F. Hannay, Borys Korchin, Fernanda I. Staquicini, Suren Soghomonyan, Mian M. Alauddin, Robert S. Benjamin, Raphael E. Pollock, Juri G. Gelovani, Renata Pasqualini, Wadih Arap

Research output: Contribution to journal › Article › peer-review

70 Scopus citations

Abstract

Human sarcomas are rare but diverse malignant tumors derived from mesenchymal tissue. Clinical response to therapy is currently determined by the modified World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST), but these standards correlate poorly with sarcoma patient outcome. We introduced ligand-directed particles with elements of AAV and phage (AAVP) to enable integration of tumor targeting to molecular imaging. We report drug-response monitoring and prediction in a nude rat model of human sarcoma by AAVP imaging. As a proof-of-concept, we imaged Herpes simplex thymidine kinase in a clinic-ready setting with PET to show that one can a priori predict tumor response to a systemic cytotoxic. Given the target expression in patient-derived sarcomas, this platform may be translated in clinical applications. Sarcoma-specific ligands and promoters may ultimately lead to an imaging transcriptome.

Original language	English (US)
Pages (from-to)	4471-4476
Number of pages	6
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	105
Issue number	11
DOIs	https://doi.org/10.1073/pnas.0712184105
State	Published - Mar 18 2008

ASJC Scopus subject areas

General

MD Anderson CCSG core facilities

Advanced Technology Genomics Core
Research Animal Support Facility
Small Animal Imaging Facility

Access to Document

10.1073/pnas.0712184105

Cite this

Hajitou, A., Lev, D. C., Hannay, J. A. F., Korchin, B., Staquicini, F. I., Soghomonyan, S., Alauddin, M. M., Benjamin, R. S., Pollock, R. E., Gelovani, J. G., Pasqualini, R., & Arap, W. (2008). A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proceedings of the National Academy of Sciences of the United States of America, 105(11), 4471-4476. https://doi.org/10.1073/pnas.0712184105

Hajitou, A, Lev, DC, Hannay, JAF, Korchin, B, Staquicini, FI, Soghomonyan, S, Alauddin, MM, Benjamin, RS, Pollock, RE, Gelovani, JG, Pasqualini, R & Arap, W 2008, 'A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 11, pp. 4471-4476. https://doi.org/10.1073/pnas.0712184105

@article{621c4786bb904db4998fbb20f09cfe6f,

title = "A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging",

abstract = "Human sarcomas are rare but diverse malignant tumors derived from mesenchymal tissue. Clinical response to therapy is currently determined by the modified World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST), but these standards correlate poorly with sarcoma patient outcome. We introduced ligand-directed particles with elements of AAV and phage (AAVP) to enable integration of tumor targeting to molecular imaging. We report drug-response monitoring and prediction in a nude rat model of human sarcoma by AAVP imaging. As a proof-of-concept, we imaged Herpes simplex thymidine kinase in a clinic-ready setting with PET to show that one can a priori predict tumor response to a systemic cytotoxic. Given the target expression in patient-derived sarcomas, this platform may be translated in clinical applications. Sarcoma-specific ligands and promoters may ultimately lead to an imaging transcriptome.",

author = "Amin Hajitou and Lev, {Dina C.} and Hannay, {Jonathan A.F.} and Borys Korchin and Staquicini, {Fernanda I.} and Suren Soghomonyan and Alauddin, {Mian M.} and Benjamin, {Robert S.} and Pollock, {Raphael E.} and Gelovani, {Juri G.} and Renata Pasqualini and Wadih Arap",

year = "2008",

month = mar,

day = "18",

doi = "10.1073/pnas.0712184105",

language = "English (US)",

volume = "105",

pages = "4471--4476",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "National Academy of Sciences",

number = "11",

}

TY - JOUR

T1 - A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging

AU - Hajitou, Amin

AU - Lev, Dina C.

AU - Hannay, Jonathan A.F.

AU - Korchin, Borys

AU - Staquicini, Fernanda I.

AU - Soghomonyan, Suren

AU - Alauddin, Mian M.

AU - Benjamin, Robert S.

AU - Pollock, Raphael E.

AU - Gelovani, Juri G.

AU - Pasqualini, Renata

AU - Arap, Wadih

PY - 2008/3/18

Y1 - 2008/3/18

N2 - Human sarcomas are rare but diverse malignant tumors derived from mesenchymal tissue. Clinical response to therapy is currently determined by the modified World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST), but these standards correlate poorly with sarcoma patient outcome. We introduced ligand-directed particles with elements of AAV and phage (AAVP) to enable integration of tumor targeting to molecular imaging. We report drug-response monitoring and prediction in a nude rat model of human sarcoma by AAVP imaging. As a proof-of-concept, we imaged Herpes simplex thymidine kinase in a clinic-ready setting with PET to show that one can a priori predict tumor response to a systemic cytotoxic. Given the target expression in patient-derived sarcomas, this platform may be translated in clinical applications. Sarcoma-specific ligands and promoters may ultimately lead to an imaging transcriptome.

AB - Human sarcomas are rare but diverse malignant tumors derived from mesenchymal tissue. Clinical response to therapy is currently determined by the modified World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST), but these standards correlate poorly with sarcoma patient outcome. We introduced ligand-directed particles with elements of AAV and phage (AAVP) to enable integration of tumor targeting to molecular imaging. We report drug-response monitoring and prediction in a nude rat model of human sarcoma by AAVP imaging. As a proof-of-concept, we imaged Herpes simplex thymidine kinase in a clinic-ready setting with PET to show that one can a priori predict tumor response to a systemic cytotoxic. Given the target expression in patient-derived sarcomas, this platform may be translated in clinical applications. Sarcoma-specific ligands and promoters may ultimately lead to an imaging transcriptome.

UR - http://www.scopus.com/inward/record.url?scp=41949106969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949106969&partnerID=8YFLogxK

U2 - 10.1073/pnas.0712184105

DO - 10.1073/pnas.0712184105

M3 - Article

C2 - 18337507

AN - SCOPUS:41949106969

SN - 0027-8424

VL - 105

SP - 4471

EP - 4476

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 11

ER -

A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this